Document is current

Article History

Received: 26 January 2026

Accepted: 14 May 2026

First Online: 15 June 2026

Competing interests

: C.L.P. received honoraria from Ipsen Biopharmaceuticals. There are no competing non-financial interests. G.D. is an employee and options holder of Pangea Biomed. CDHL has no financial or non-financial conflicts of interest to declare. S.S. received honoraria from Pfizer. There are no competing non-financial interests. JB is on the scientific advisory board of Bowhead Health. There are no competing non-financial interests. O.T. is an employee and options holder of Pangea Biomed. S.R.D. has no financial or non-financial conflicts of interest to declare. D.T.H. is an inventor of a patent (US 20250201343A1) filed based on the ENLIGHT-DeepPT framework. There are no competing non-financial interests. T.B. is an employee and options holder of Pangea Biomed. E.S. has no financial or non-financial conflicts of interest to declare. AS received honoraria or consultation fees from Merck, Bristol-Myers Squibb, GSK, BeiGene, Alentis, and Pfizer; leads a collaborative initiative with Boehringer Ingelheim; received grant/research support (institutional) from Novartis, Bristol-Myers Squibb, Symphogen AstraZeneca/Medimmune, Merck, Bayer, Surface Oncology, Janssen Oncology/Johnson & Johnson, Roche, Regeneron, Alkermes, Array Biopharma/Pfizer, GSK, Oncorus, BI, Treadwell, Amgen, ALX Oncology, Genentech, Seagen, Servier, Incyte, Alentis, Merus, Teva Terapeutics, EMD Serono, and Auricula Biosciences. There are no competing non-financial interests. PLB received honoraria or consultation fees from Boehringer Ingelheim, Bayer, and Daiichi Sankyo/UCB Japan, received grant/research support (institutional) from Bristol-Myers Squibb, Sanofi; AstraZeneca, Genentech/Roche, GlaxoSmithKline, Novartis, Merc,; Seagen, Lilly, Amgen, Bicara Therapeutics, Zymeworks, Medicenna, Bayer, Takeda, Gilead Sciences, LegoChem Biosciences, Boehringer Ingelheim, ProteinQure, Daiichi Sankyo/UCB Japan, and ALX Oncology; participates on the data safety and monitoring board of Relay Therapeutics, Lilly, and Myeloma Cancer Research Network. There are no competing non-financial interests. S.G. has received grant/research support (institutional) from Astra-Zeneca. There are no competing non-financial interests. A.R.A.R. received honoraria or consultation fees from Boehringer Ingleheim, Medison and Clinical Research Malaysia; received grant/research support (institutional) from 23&Me, Abbisko, AbbVie, Adaptimmune, Amgen, Astra Zeneca, Bayer, Biontech, Blueprint Medicine, Boehringer Ingleheim, Bristol Myers Squibb, Cogent Biosciences, Daiichi Sankyo, Deciphera, Frontier Biopharma, Gilead, GlaxoSmithKline, Iterion Therapeutics, Karyopharm Therapeutics, Kelun Therapeutics MedImmune, Medison, Merck, Neoleukin, Novartis, Pfizer, Polaris, Roche/Genentech, Rain Therapeutics and Symphogen; participates on the data safety and monitoring board of Inhibrx and Life CD40. There are no competing non-financial interests. ER is a co-founder of Pangea Biomed (divested), and an unpaid member of Pangea Biomed, GSK Oncology and ProCan scientific advisory boards.RA is an employee and options holder of Pangea Biomed. LLS received honoraria or consultation fees from Merck, Roche, Voronoi, GSK, Bayer, Pfizer, Arvinas, Daiichi Sankyo, Amgen, Pangea, Tubulis, LTZ Therapeutics, Marengo, AstraZeneca, Incyte, Gilead, Bristol-Myers Squibb, Systimmune and EMD Serono; received grant/research support (institutional) from Bristol-Myers Squibb, Roche/Genentech, GSK, Merck, Novartis, Pfizer, AstraZeneca, Boehringer-Ingelheim, Bayer, Amgen, Abbvie, EMD Serono, Daiichi Sankyo, Gilead, Marengo, Incyte, Legochem, Loxo/Lilly, and Daiichi Sankyo; spouse/partner is the cofounder of Treadwell Therapeutics. There are no competing non-financial interests.